John Gorcsan, MD presented “Association of persistent or worsened echocardiographic dyssynchrony with unfavorable clinical outcomes in heart failure patients with narrow QRS width: a subgroup of analysis of the EchoCRT trial” at the European Society of Cardiology 2015 Congress in London, England. He discussed how while the trial showed no benefit for cardiac resynchronization therapy (CRT) for heart failure patients, a sub-study of more than 800 patients from around the world revealed that abnormalities in mechanical activation – or dyssynchrony – were markers for more advanced disease and higher incidence of follow-up heart failure, hospitalizations, and even death. With this information, cardiologists will be able to better apply CRT to more appropriate patient populations.

Read the abstract here.

Hear more about this work from Dr. Gorcsan: